Posted by Michael Wonder on 12 Dec 2023
Efgartigimod for the treatment of patients with generalised myasthenia gravis (draft guidance 2)
12 December 2023 - NICE has published further draft guidance on the use of efgartigimod for the treatment of patients with generalised myasthenia gravis.
Efgartigimod is still not recommended for use as an add-on to standard treatment for adults with generalised myasthenia gravis who test positive for anti-acetylcholine receptor antibodies.
